Cargando…

Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome

PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xi-Mei, Zhang, Yun-Bo, Chi, Mei-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800359/
https://www.ncbi.nlm.nih.gov/pubmed/26996569
http://dx.doi.org/10.3349/ymj.2016.57.3.681
_version_ 1782422470708428800
author Zhang, Xi-Mei
Zhang, Yun-Bo
Chi, Mei-Hua
author_facet Zhang, Xi-Mei
Zhang, Yun-Bo
Chi, Mei-Hua
author_sort Zhang, Xi-Mei
collection PubMed
description PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. RESULTS: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessment for insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, -0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and C-reactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (≥6 mo) significantly reduced FPG, LDL-C, and CRP, while that for a shorter duration (<6 mo) significantly reduced FSI and HOMA-IR. CONCLUSION: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma.
format Online
Article
Text
id pubmed-4800359
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-48003592016-05-01 Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome Zhang, Xi-Mei Zhang, Yun-Bo Chi, Mei-Hua Yonsei Med J Original Article PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. RESULTS: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessment for insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, -0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and C-reactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (≥6 mo) significantly reduced FPG, LDL-C, and CRP, while that for a shorter duration (<6 mo) significantly reduced FSI and HOMA-IR. CONCLUSION: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma. Yonsei University College of Medicine 2016-05-01 2016-03-15 /pmc/articles/PMC4800359/ /pubmed/26996569 http://dx.doi.org/10.3349/ymj.2016.57.3.681 Text en © Copyright: Yonsei University College of Medicine 2016 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhang, Xi-Mei
Zhang, Yun-Bo
Chi, Mei-Hua
Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title_full Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title_fullStr Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title_full_unstemmed Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title_short Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
title_sort soy protein supplementation reduces clinical indices in type 2 diabetes and metabolic syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800359/
https://www.ncbi.nlm.nih.gov/pubmed/26996569
http://dx.doi.org/10.3349/ymj.2016.57.3.681
work_keys_str_mv AT zhangximei soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome
AT zhangyunbo soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome
AT chimeihua soyproteinsupplementationreducesclinicalindicesintype2diabetesandmetabolicsyndrome